Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 8/20 | 0.41 |
| ▸ | CCKBR | P32239 | 8/20 | 0.41 |
| ▸ | CD40 | P25942 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20041046 | 0.97 | AKT1 (0.45) | AKT1CCKARCCKBRALDH1A1SMN1; SMN2 | |
| SCHEMBL20345224 | 0.97 | AKT1 (0.45) | AKT1CCKARCCKBRALDH1A1SMN1; SMN2 | |
| SCHEMBL26170798 | 0.92 | OPRD1 (0.43) | AKT1 | |
| SCHEMBL25871152 | 0.91 | AKT1 (0.45) | AKT1CCKARCCKBRALDH1A1SMN1; SMN2 | |
| SCHEMBL25877099 | 0.91 | AKT1 (0.43) | AKT1CD40ALDH1A1SMN1; SMN2 | |
| SCHEMBL28385639 | 0.90 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22768342 | 0.90 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28385636 | 0.90 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18224261 | 0.90 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17003582 | 0.90 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | AKT1 2403/4885CCKAR 876/4885CCKBR 1459/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | AKT1 2403/4885CCKAR 876/4885CCKBR 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.